Added 7 hours ago Drug news
ATLAS-2M study met its primary endpoint for cabotegravir and rilpivirine administered every eight weeks compared to four-week administration. Viiv HealthCare
ViiV Healthcare, announced positive headline results from its global phase III ATLAS-2M study of the investigational, long-acting, injectable, 2-drug regimen...
Added 12 days ago Drug news
Gilead Sciences, Inc. announced that the Antimicrobial Drugs Advisory Committee (AMDAC) of the FDA recommended approval of Descovy...
Added 16 days ago Drug news
Gilead Sciences Canada, Inc. announced that effective July 31, the Ontario Drug Benefit Program will provide eligible patients with access...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
EADV Congress 2018: Bringing you the latest news and insights from 27th EADV Congress, 12-16 September 2018 Paris, France.
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.
The overall purpose of these guidelines is to provide guidance on best clinical practice in the treatment and management of pregnant women living with HIV (human immunodeficiency virus) in the UK and their infants.
Added 5 years ago
EACS produces the European Guidelines for treatment of HIV-positive adults in Europe.
Added 1 year ago
British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-positive individuals 2016
As with the previous monitoring guideline, the aim is to present a consensus regarding the standard assessment and investigation of HIV infection from the time of diagnosis and to describe the appropriate monitoring of HIV-positive individuals...
Added 7 years ago
An HIV-1-infected adult underwent allo-HSCT for Hodgkin's lymphoma using cells from a CCR5Δ32/Δ32 donor. He experienced mild gut graft versus host disease.
Added 5 months ago
The authors present and discuss the efficacy and safety data of DRV when used in antiretroviral-naïve, multiexperienced subjects and in the setting of treatment deintensification in subjects with viral suppression.
Added 1 year ago
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Bictegravir, co-formulated with emtricitabine and tenofovir alafenamide, has shown good efficacy and tolerability, and similar bone, renal, and lipid profiles to dolutegravir, abacavir, and lamivudine, in treatment-naive adults with HIV-1...
Added 1 year ago
Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults (Alliance)
The primary objective of this study is to evaluate the efficacy of fixed-dose combination (FDC) of bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + emtricitabine/tenofovir disoproxil fumarate...
Added 1 month ago
A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care
The purpose of this study is to assess the efficacy of Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) fixed-dose combination (FDC) in a Test and Treat model of care in newly diagnosed human immunodeficiency virus...
Added 11 months ago
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
This study will compare safety, efficacy, and tolerability of a two drug regimen of dolutegravir (DTG) plus (+) lamivudine (3TC) administered once daily with DTG plus two nucleoside reverse transcriptase inhibitors...
Added 1 year ago
I am a retired infectious disease physician with a particular interest in blood borne viruses (HIV/viral hepatitis), neurological infection and bone & joint infection. I now work part time in acute medicine and part time in medical training & education as deputy Medical Director of... Read more
At first sight this seems a question with an obvious response and not one that requires much debate in this blog. However, the answer may be more complex than it initially appears and may benefit from further exploration.